Press "Enter" to skip to content

AstraZeneca Vaccine Approval Unlikely In January: European Union Agency

The AstraZeneca-Oxford vaccine is at the moment present process a “rolling review”.

The Hague, Netherlands:

The coronavirus vaccine developed by AstraZeneca and Oxford University, which was authorised Wednesday in Britain, is unlikely to get a inexperienced mild within the European Union within the subsequent month, in line with the European Medicines Agency (EMA).

The regulator, charged with overseeing vaccines’ authorisation within the EU earlier than they are often marketed, authorised the Pfizer-BioNTech vaccine on December 21. It is predicted to rule on Moderna’s vaccine on January 6.

“No formal marketing authorisation has yet been submitted to EMA, therefore EMA’s committee for human medicines has not yet set a timetable” for approving the AstraZeneca-Oxford jab, the Amsterdam-based company instructed AFP.

The regulator’s deputy government director Noel Walthion instructed Belgian newspaper Het Nieuwsblad on Tuesday {that a} doable approval in January is “unlikely,” an announcement confirmed by the company late Tuesday.

The AstraZeneca-Oxford vaccine is at the moment present process a “rolling review” which permits the EMA to look at security and efficacy information as they’re launched, even earlier than a proper utility for authorisation is filed by the producer.

This process quickens the analysis of a advertising authorisation utility as soon as it’s made, the EMA mentioned.

Newsbeep

Britain on Wednesday grew to become the primary nation on the planet to approve the vaccine, which is cheaper to provide and simpler to retailer and transport than the Pfizer-BioNTech jab.

For EU international locations, it’s as much as the European Commission in Brussels to problem the ultimate inexperienced mild after EMA approval.

Inoculations with the Pfizer-BioNTech vaccine started within the 27-member bloc over the weekend.

(Except for the headline, this story has not been edited by NDTV employees and is printed from a syndicated feed.)

Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    %d bloggers like this: